INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE /// EXPLORE NOW INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE ///

Dr. Arul Chinnaiyan joins Tempus as Scientific Adviser

PRESS RELEASES

05/02/2016

Arul Chinnaiyan, M.D., Ph.D, a renowned leader in the study of cancer genomics, has joined Tempus as a Scientific Adviser. In this role, he will bring his expertise translating groundbreaking genomic research into the clinic.

“Arul has spent the last 15 years researching how changes in the genome relate to cancer,” said Kevin White, President of Tempus. “He is a leader in translating his findings into information that is clinically actionable for oncologists who are treating cancer.”

Dr. Chinnaiyan is the S.P. Hicks Endowed Professor of Pathology, Director of the Michigan Center for Translational Pathology (MCTP) and a Howard Hughes Medical Institute Investigator in patient-oriented research and an American Cancer Society Research Professor.

Dr. Chinnaiyan’s lab at the University of Michigan is focused on functional genomic, proteomic and bioinformatics approaches to study cancer for the purposes of understanding cancer biology as well as to discover clinical biomarkers.

“I am thrilled to be advising Tempus, as we share a common passion to create innovative tools to empower oncologists with information that can help them deliver better care to, and ultimately outcomes for, their patients,” said Chinnaiyan.

Dr. Chinnaiyan received his medical degree and doctorate in pathology from the University of Michigan.